Form 4: Tandem Diabetes EVP Exercises RSUs, Adjusts Holdings

Tandem Diabetes Care's EVP & Chief Legal Officer, Shannon Marie Hansen, reported the exercise of restricted stock units and subsequent tax-related share withholdings.

Summary

• Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions involving the vesting and conversion of Restricted Stock Units (RSUs) into common stock.
• On February 17, 2026, a total of 3,065 shares of common stock were acquired through the exercise of RSUs at a price of $0.
• Concurrently, 1,263 shares were disposed of to satisfy tax withholding requirements related to the RSU vesting, at a price of $18.95 per share.
• Following these transactions, Ms. Hansen directly beneficially owns 23,276 shares of common stock.
• Additionally, 1,935 shares are indirectly beneficially owned through the Shannon M. Hansen Trust dated July 8, 2003.
• Remaining derivative securities include 1,437 Restricted Stock Units from the May 25, 2023 award and 5,484 Restricted Stock Units from the May 23, 2024 award.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It reflects the routine execution of an executive compensation plan and does not indicate any material positive or negative developments for the company.

Positives

• The vesting of Restricted Stock Units indicates continued executive compensation and retention, aligning management's interests with shareholder value.
• The acquisition of common stock at a $0 exercise price reflects the realization of previously granted equity awards.

Negatives

• The disposition of 1,263 shares was solely for tax withholding purposes, which is a routine event and not indicative of a negative outlook on the company by the insider.

Future Outlook

Future vesting events for outstanding Restricted Stock Units are scheduled. The RSU awarded on May 25, 2023, will continue to vest in eight equal quarterly installments after May 15, 2024. The RSU awarded on May 23, 2024, will continue to vest in eight equal quarterly installments after May 15, 2025.

Industry Context

StockSavvy.ai notes that this Form 4 filing represents a routine insider transaction, common across publicly traded companies. The vesting of Restricted Stock Units and subsequent tax withholding is a standard component of executive compensation packages, designed to incentivize long-term performance and align management interests with shareholders. This type of filing typically does not signal a change in strategic direction or operational performance, but rather the execution of pre-established equity compensation plans.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widespread practice across various industries, including the medical device and biotechnology sectors where Tandem Diabetes Care operates.
• The vesting schedules (e.g., 25% on first anniversary, then quarterly; 33% on first anniversary, then quarterly) are typical for long-term incentive plans, comparable to those seen at companies like Dexcom (DXCM) or Insulet Corporation (PODD), which also operate in the diabetes management space.
• The disposition of shares solely for tax withholding is a standard mechanism for executives to cover tax liabilities upon RSU vesting, consistent with practices observed at most U.S. public companies.

Corporate Governance

Related Party Transactions

• Shares are indirectly held by the Shannon M. Hansen Trust dated July 8, 2003, of which Shannon M. Hansen is the Trustee. This is a common arrangement for executive shareholdings.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event, not a discretionary sale or purchase based on new information.
• Employees (Executive): The vesting and conversion of RSUs represent the realization of long-term incentive compensation, contributing to executive retention and motivation.

Next Steps

• Continued vesting of remaining Restricted Stock Units according to their respective schedules.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax withholding. It does not provide new fundamental information about Tandem Diabetes Care's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell the stock.

Keywords

TNDM, Tandem Diabetes Care, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Award, Tax Withholding